AZD4573
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Relapsed/Refractory Peripheral T-cell Lymphoma
Conditions
Relapsed/Refractory Peripheral T-cell Lymphoma, Relapsed/Refractory Classical Hodgkins Lymphoma
Trial Timeline
Dec 15, 2021 → Feb 16, 2024
NCT ID
NCT05140382About AZD4573
AZD4573 is a phase 2 stage product being developed by AstraZeneca for Relapsed/Refractory Peripheral T-cell Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT05140382. Target conditions include Relapsed/Refractory Peripheral T-cell Lymphoma, Relapsed/Refractory Classical Hodgkins Lymphoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05140382 | Phase 2 | Completed |
| NCT03263637 | Phase 1 | Completed |
Competing Products
20 competing products in Relapsed/Refractory Peripheral T-cell Lymphoma